The goal of this consumer health study is to evaluate the effect of resW™ Perimenopause Postbiotic on menopausal symptom severity, menopause-related quality of life, and selected microbiome-related outcomes in generally healthy perimenopausal women aged 35 to 55 years. Participants will be randomized to receive either the active supplement or placebo daily for 4 weeks. Participants will complete electronic questionnaires at baseline and during the study. A predefined subset of participants will also complete stool and vaginal sample collection at baseline and Week 4.
This is a randomized, double-blind, placebo-controlled, parallel-group consumer health study evaluating the effect of resW™ Perimenopause Postbiotic in generally healthy perimenopausal women aged 35 to 55 years. Eligible participants will be randomized in a 1:1 ratio to receive either resW™ Perimenopause Postbiotic or placebo for 4 weeks. Participants will take 2 capsules daily and complete electronic study questionnaires through the Chloe app. Menopausal symptom severity and menopause-related quality of life will be assessed using the Greene Climacteric Scale and Cervantes Short Form at baseline and Week 4, with an interim Greene Climacteric Scale assessment at Week 2. A predefined microbiome substudy subset of approximately 20 participants will complete stool and vaginal sample collection at baseline and Week 4. These samples will be used to evaluate exploratory changes in stool microbiome composition, vaginal microbiome composition, and vaginal pH. Safety and tolerability will be monitored throughout the study through adverse event reporting, compliance tracking, and participant-reported feedback.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Enrollment
80
Active supplement
Inactive supplement
Able Biolabs LLC
Dallas, Texas, United States
Change in Greene Climacteric Scale total score from baseline to Week 4
Change from baseline to Week 4 in the Greene Climacteric Scale total score. The Greene Climacteric Scale is a 21-item questionnaire assessing climacteric symptoms. Total scores range from 0 to 63, with higher scores indicating greater climacteric symptom severity, which is a worse outcome.
Time frame: Baseline to Week 4
Changes in gut microbiota composition associated with hormonal health
Change from baseline to Week 4 in gut microbiota composition assessed using stool sample microbiome sequencing. Gut microbiota composition will be evaluated by measures including microbial taxonomic relative abundance and diversity metrics derived from sequencing data. This outcome will assess changes in the composition of bacterial taxa in stool samples associated with hormonal health.
Time frame: 4 weeks
Change in Cervantes Short Form total score from baseline to Week 4
Change from baseline to Week 4 in the Cervantes Short Form Scale total score. The Cervantes Short Form Scale is a validated menopause-specific quality-of-life questionnaire assessing menopause-related quality of life across physical, psychological, and aging-related domains. Total scores range from 0 to 100, with higher scores indicating poorer menopause-related quality of life, which is a worse outcome.
Time frame: Baseline to Week 4
Change in stool microbiome alpha diversity from baseline to Week 4
Change from baseline to Week 4 in stool microbiome alpha diversity, assessed using diversity indices such as the Shannon diversity index, Simpson diversity index, or observed amplicon sequence variants/species richness, in participants enrolled in the microbiome substudy.
Time frame: Baseline to Week 4
Change in stool microbial taxonomic composition from baseline to Week 4
Change from baseline to Week 4 in the relative abundance of stool microbial taxa, assessed using stool sample microbiome sequencing, in participants enrolled in the microbiome substudy.
Time frame: Baseline to Week 4
Change in vaginal microbiome alpha diversity from baseline to Week 4
Change from baseline to Week 4 in vaginal microbiome alpha diversity, assessed using diversity indices such as the Shannon diversity index, Simpson diversity index, or observed amplicon sequence variants/species richness, in participants enrolled in the microbiome substudy.
Time frame: Baseline to Week 4
Change in relative abundance of vaginal microbial taxa from baseline to Week 4
Change from baseline to Week 4 in the relative abundance of vaginal microbial taxa, including Lactobacillus species and bacterial vaginosis-associated taxa, assessed using vaginal sample microbiome sequencing, in participants enrolled in the microbiome substudy.
Time frame: Baseline to Week 4
Change in vaginal pH from baseline to Week 4
Change from baseline to Week 4 in vaginal pH, measured from vaginal samples using a pH test method, in participants enrolled in the microbiome substudy. Vaginal pH is measured on a continuous scale, with higher values indicating greater vaginal alkalinity.
Time frame: Baseline to Week 4
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.